TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
BUY ON WEAKNESS

Pfizer Inc(PFE)

Apr 05, 2010
(Market Call Minute) If it came down a little bit be would be much more interested.
Photo of Benj GallanderBenj GallanderUnlock Rating
$16.90

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 25, 2010
Great company with a great yield and trading at a very low multiple. Pharmaceutical industry made so much money on their blockbuster drugs but that dried up. This company has made some good acquisitions and are continuing to cut costs. Pipeline is reasonable but you're not going to see the big blockbuster drugs in the next several years.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$17.39

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 24, 2010
Wouldn't own any US pharmaceutical companies. Research pipeline cupboard is really bare. Doesn't see any growth. A lot of generic competition.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$17.61

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 23, 2010
Pfizer (PFE-N) and Merck (MRK-N) are pretty fully priced at current levels. Growth prospects are not that great, especially with a lot of drugs coming off patent. Multiple looks attractive and dividend looks okay but there are better places to go in pharmaceuticals. Prefers Abbott Labs (ABT-N).
Photo of Don LatoDon Lato
No
Unlock Rating
$17.54

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Feb 17, 2010
One of the mega pharmas that is having trouble getting traction because it is so large. They have a problem with one of their large drugs (25% of business) coming off patent within the next year. He would look elsewhere. J&J, Abbot, are better picks.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$17.67

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 03, 2010
Model price of $29.40, a 53% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$18.62

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 03, 2010
Just reported lower-than-expected earnings. Chart shows a strong upward trend so technically it still looks good. Usually healthcare stocks do very well from July to October.
Photo of Don VialouxDon VialouxUnlock Rating
$18.62

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 28, 2010
(A Top Pick Jan 27/09. Up 25.12%.) Likes the outlook for drug stocks. Still a Buy.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$18.63

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Track your Stocks in your Watch List
BUY

Pfizer Inc(PFE)

Jan 14, 2010
Have their challenges with patent expiries but a huge global player with very good exposure to emerging markets. Reasonable dividend. 3.7% yield.
Photo of Jeff BlackJeff BlackUnlock Rating
$19.38

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 13, 2010
Loss of their Lipitor patent in 2011 (25% of revenues) is priced into the stock but this is a problem with all Pharma plays. Patent expirations is hugely punitive. (See Top Picks.)
Photo of Gordon ReidGordon ReidUnlock Rating
$19.21

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 23, 2009
(A Top Pick Jan 27/09. Up 17.5%.) The world hated pharmaceutical stocks but started to like them more. All the major pharmas have patents coming off in the next 5 years. This is already built into the price. Companies have all built up big cash reserves.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$18.58

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 15, 2009
Biovail is the only Canadian equivalent. He likes the industry. Concern as patents expire. Market has valued this concern into the price. Continue to generate cash flow. Prefers Merck.
Photo of Ara NalbandianAra Nalbandian
No
Unlock Rating
$18.29

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 16, 2009
US healthcare stocks were ignored until recently. Recently completed its acquisition of Wyeth, which gives them a new product pipeline. 3.7% yield.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$17.94

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 06, 2009
The issue here is Lipitor patents coming off in 2010 and they have to fill the product pipeline with something that is going to be a blockbuster. Question that they can use their cash horde effectively to fill the R&D pipeline, get new products to market and get their profits up. (See Top Picks.)
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$16.96

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 04, 2009
About the 50-day and 200-day moving averages and is continuing to climb. 3.7% dividend and they are due for an increase.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$16.93

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 466 to 480 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like